Subcutaneous Implantable Cardioverter-Defibrillators in Patients With Congenital Heart Disease.
Victor WaldmannChristelle MarquiéFrancis BessièreDavid PerrotFrédéric AnselmeNicolas BadencoSergio BarraGéraldine BertauxHugues BlangyPierre BordacharSerge BovedaMichel ChauvinNicolas ClémentyGaël ClericiNicolas CombesPascal DefayeJean-Claude DeharoPhilippe DurandGuillaume DuthoitRomain EschalierLaurent FauchierRodrigue GarciaOlivier GeoffroyEdouard GitenayJean-Baptiste GourraudCharles GuenanciaLaurence IserinPeggy JaconLaurence Jesel-MorelFawzi KerkouriDidier KlugLinda KoutbiFabien LabombardaMagalie LadouceurGabriel LaurentChristophe LeclercqBaptiste MailleAlice MaltretGrégoire MassouliéPierre MondolySandro NinniPierre OllitraultJean-Luc PasquiéBertrand PierrePénélope PujadasLaure Champ-RigotFrédéric SacherNicolas SadoulAlexandre SchatzPierre WinumPaul-Ursmar MilliezVincent ProbstEloi MarijonPublished in: Journal of the American College of Cardiology (2023)
In this nationwide study, patients with CHD represented 2% of all S-ICD implantations. Our findings emphasize the effectiveness and safety of S-ICD in this particularly high-risk population. (S-ICD French Cohort Study [HONEST]; NCT05302115).